2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multiple sclerosis

, Ribbons, Karen, Arm, Jameen, Al-Iedani, Oun, Lechner-Scott, Jeannette, , & Ramadan, Saadallah (2019) 2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multiple sclerosis. Therapeutic Advances in Neurological Disorders, 12.

Open access copy at publisher website

Description

Background: We have applied in vivo two-dimensional (2D) localized correlation spectroscopy (2D L-COSY), in treated relapsing relapsing-remitting multiple sclerosis (RRMS) to identify novel biomarkers in normal-appearing brain parenchyma. Methods: 2D L-COSY magnetic resonance spectroscopy (MRS) spectra were prospectively acquired from the posterior cingulate cortex (PCC) in 45 stable RRMS patients undergoing treatment with Fingolimod, and 40 age and sex-matched healthy control (HC) participants. Average metabolite ratios and clinical symptoms including, disability, cognition, fatigue, and mental health parameters were measured, and compared using parametric and nonparametric tests. Whole brain volume and MRS voxel morphometry were evaluated using SIENAX and the SPM LST toolbox. Results: Despite the mean whole brain lesion volume being low in this RRMS group (6.8 ml) a significant reduction in PCC metabolite to tCr ratios were identified for multiple N-acetylaspartate (NAA) signatures, gamma-aminobutyric acid (GABA), glutamine and glutamate (Glx), threonine, and isoleucine/lipid. Of the clinical symptoms measured, visuospatial function, attention, and memory were correlated with NAA signatures, Glx, and isoleucine/lipid in the brain. Conclusions: 2D L-COSY has the potential to detect metabolic alterations in the normal-appearing MS brain. Despite examining only a localised region, we could detect metabolic variability associated with symptoms.

Impact and interest:

8 citations in Scopus
6 citations in Web of Science®
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

Full-text downloads:

26 since deposited on 28 Apr 2022
10 in the past twelve months

Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.

ID Code: 230182
Item Type: Contribution to Journal (Journal Article)
Refereed: Yes
Additional Information: Funding Information: Funding for this study provided by Novartis Pharmaceuticals Australia.
Measurements or Duration: 16 pages
Keywords: 2D L-COSY, Magnetic Resonance, MRS, Multiple Sclerosis, RRMS, Spectroscopy
DOI: 10.1177/1756286419877081
ISSN: 1756-2856
Pure ID: 108868576
Divisions: Past > Institutes > Institute of Health and Biomedical Innovation
Funding Information: The processing parameters used were: F2 domain (skewed sine-squared window, 2048 points, magnitude mode), F1 domain (sine-squared window, linear prediction to 96 points, zero-filling to 512 points, magnitude mode). No additional water removal was applied, as water was sufficiently suppressed during acquisition. The volumes of cross peaks, or diagonal resonances, were evaluated using Felix software described above, and care was taken to ensure that the interrogated volume was the same in all 2D spectra, using a peak template with fixed chemical shift values. We would like to acknowledge all the study participants that took part in this investigation. Funding The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: Funding for this study provided by Novartis Pharmaceuticals Australia. Conflict of interest statement The authors declare that there is no conflict of interest. ORCID iD Scott Quadrelli https://orcid.org/0000-0002-6626-9825
Copyright Owner: 2019 The Author(s)
Copyright Statement: This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au
Deposited On: 28 Apr 2022 01:50
Last Modified: 03 Mar 2024 06:38